Understanding how lung cancer changes to become more aggressive
Defining and overcoming lineage plasticity in lung cancer
This study is looking at how lung adenocarcinoma can change into a tougher type of lung cancer called small cell lung cancer, which is harder to treat, and it aims to find out what genetic changes happen during this process so that new treatments can be developed to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11050298 on NIH RePORTER |
What this research studies
This research investigates how lung adenocarcinoma can transform into a more aggressive form known as small cell lung cancer, which is often resistant to treatment. By examining clinical samples, the study aims to identify the genetic and molecular changes that occur during this transformation. The researchers will focus on specific alterations in genes and signaling pathways that may contribute to this process. Ultimately, the goal is to develop new therapies that can prevent or reverse this transformation, improving treatment options for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with EGFR-mutant lung adenocarcinoma who may be at risk of developing small cell lung cancer.
Not a fit: Patients with lung cancer types other than adenocarcinoma or those without EGFR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent the progression of lung cancer to a more aggressive form, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in understanding cancer lineage plasticity, but this specific approach targeting EGFR-mutant lung cancer is relatively novel.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Sen, Triparna — Icahn School of Medicine at Mount Sinai
- Study coordinator: Sen, Triparna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.